Tucatinib: observed
6 studies: patients on it are followed, or it is given outside a trial. Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.
- GIM27-THERapy: a Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER-2 Positive Breast Cancer Patients in Real World SettingRecruitingNCT07583485Report a problem
- A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug as a Radiosensitizer in Patients With Advanced Breast Cancer Brain Metastasis.RecruitingNCT06839547Report a problem
- Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.CompletedNCT06961331Report a problem
- Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.CompletedNCT05253911Report a problem
- Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast CancerApproved for marketingNCT04220203Report a problem
- Expanded Access Use of Tucatinib for HER2+ Metastatic Breast CancerNo longer availableNCT03424473Report a problem